Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Locally Recurrent Skin Squamous Cell Carcinoma × (225)Ac-DOTA-c(RGDyK) × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 6 Mouth Neoplasms 4 Laryngeal Neoplasms 4 Hypopharyngeal Neoplasms 4 Carcinoma 4 Oropharyngeal Neoplasms 3 Nasopharyngeal Carcinoma 1 Lymphoid Interstitial Pneumonia 1 Locally Recurrent Skin Squamous Cell Carcinoma 1 Colorectal Neoplasms 1

Interventions

amivantamab 1 Specimen Handling 1 Magnetic Resonance Spectroscopy 1 Hyaluronoglucosaminidase 1 Cetuximab 1 (225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07042295 2026-03-18

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Recruiting

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡